Key Takeaway: Nkarta has reported its financial results for the second quarter of 2026, highlighting ongoing enrollment in its Ntrust-1 and Ntrust-2 clinical trials at a high cell dose level. The company anticipates presenting initial clinical data from these trials at a medical conference in 2026. As of June 30, 2026, Nkarta's cash balance stands at $243.2 million.
Market Sentiment Analysis
POSITIVE FACTORS
Enrollment is ongoing across all indications in Ntrust-1 and Ntrust-2.
Initial clinical data is expected to be presented at a medical conference in 2026.
The company has a strong cash balance of $243.2 million.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~22 mo
Low dilution risk
Lead asset
NKX101 - CAR NK cell therapy
Phase 1 · Relapsed/Refractory AML
Full Press Release Details
Enrollment continues across all indications in Ntrust-1 and Ntrust-2 at the 4 billion cell dose level (12 billion cells in 3-dose cycle) Initial clinical data from Ntrust-1 and Ntrust-2 expected to be presented at a medical conference in 2026 Cash balance of $243.2 million on June 30, 2026,
Frequently Asked Questions
What are the key highlights from Nkarta's Q2 2026 report?
Nkarta reported ongoing enrollment in Ntrust-1 and Ntrust-2 trials and a cash balance of $243.2 million.
When will Nkarta present initial clinical data?
Initial clinical data from Ntrust-1 and Ntrust-2 is expected to be presented at a medical conference in 2026.
What is the cell dose level for Nkarta's trials?
The trials are being conducted at a 4 billion cell dose level, with a total of 12 billion cells in a 3-dose cycle.